Daiichi Sankyo: Kidney Diseases trials
The registry lists 13 Kidney Diseases studies with Daiichi Sankyo as lead sponsor. 0 are open to participants now and 6 have results posted.
Phase 1 1Phase 2 2Phase 3 7Phase 4 2No phase 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Safety Study of DS-5565 for Treatment of Fibromyalgia Pain in Subjects With Chronic Kidney DiseaseCompletedNCT02496884Phase 3Results posted
- Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease PatientsCompletedNCT00548691Phase 3Results posted
- VIT45 Versus Oral Iron in the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney DiseaseCompletedNCT00317239Phase 3Results posted
- Long Term Safety Study of (VIT45) Extension Study: Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney DiseaseCompletedNCT00317226Phase 3Results posted
- Safety and Efficacy of Iron Sucrose in ChildrenCompletedNCT00239642Phase 4Results posted
- ORIENT: Olmesartan Reducing Incidence of End Stage Renal Disease in Diabetic Nephropathy TrialCompletedNCT00141453Phase 3Results posted
- Registry to Evaluate Maintenance Treatment With Venofer in Pediatric Patients With Chronic Kidney DiseaseCompletedNCT02492672
- A Study to Evaluate Efficacy and Safety of CS-3150 in Japanese Type 2 Diabetic Subjects With MicroalbuminuriaCompletedNCT02345057Phase 2
- Pilot PK/PD Study of DS-1093a in Patients With Chronic Kidney DiseaseCompletedNCT02299661Phase 1
- Safety Assessment of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)WithdrawnNCT01151592Phase 4
- Study of Olmesartan Medoxomil (CS-866) in Patients With Chronic Glomerulonephritis or Diabetic NephropathyCompletedNCT00914524Phase 2
- Olmesartan Medoxomil and Diabetic NephropathyCompletedNCT00362960Phase 3
- Olmesartan Medoxomil in Diabetes MellitusCompletedNCT00185159Phase 3